Propanc Biopharma, Inc. (PPCB) Financial Statements (2025 and earlier)

Company Profile

Business Address 302/6 BUTLER STREET
CAMBERWELL, VICTORIA, 3124
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
6/30/2024
12/31/2023
MRQ
6/30/2023
6/30/2022
6/30/2021
6/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,08571,65010,0474,0672,25567,007
Cash and cash equivalents21,08571,65010,0474,0672,25567,007
Receivables   2,8672,3424,3412,015
Other undisclosed current assets4,356139,1746,1258,621  
Total current assets:25,441210,82419,03915,0306,59669,022
Noncurrent Assets
Operating lease, right-of-use asset    62,523 21,682
Property, plant and equipment  503022,0234,2555,747
Deposits noncurrent assets2,0082,044 2,0752,2502,067
Deferred costs27,117     
Other undisclosed noncurrent assets17,79928,98940,987   
Total noncurrent assets:46,92431,08341,28966,6216,50529,496
TOTAL ASSETS:72,365241,90760,32881,65113,10198,518
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,947,3181,848,6641,599,0451,790,6211,420,8731,196,265
Interest and dividends payable8,000  
Employee-related liabilities415,799418,538354,109
Accounts payable1,213,3351,157,691966,718943,0231,002,335842,156
Accrued liabilities733,983690,973632,327423,799  
Debt604,019819,650455,819984,260624,5831,557,734
Deferred compensation liability     54,220177,009
Due to related parties 30,74633,34730,639
Other undisclosed current liabilities1,241,4451,093,9371,103,365257,354947,651778,296
Total current liabilities:3,792,7823,762,2513,158,2293,062,9813,080,6743,739,943
Noncurrent Liabilities
Long-term debt and lease obligation:    42,319  
Operating lease, liability    42,319  
Other undisclosed noncurrent liabilities58,64243,25519,278(42,319)  
Total noncurrent liabilities:58,64243,25519,27842,319  
Total liabilities:3,851,4243,805,5063,177,5073,105,3003,080,6743,739,943
Equity
Equity, attributable to parent, including:(3,779,059)(3,563,599)(3,117,179)(3,023,649)(3,067,573)(3,641,425)
Common stock478,80236,1696,031220,35114,056258,120
Treasury stock, value(46,477)(46,477)(46,477)(46,477)(46,477)(46,477)
Additional paid in capital61,217,25561,018,60360,311,50257,124,98254,074,11050,656,031
Accumulated other comprehensive income1,269,5811,234,0701,294,8761,234,5491,085,2041,267,671
Accumulated deficit(66,698,220)(65,797,142)(64,684,732)(61,557,893)(58,199,466)(55,781,770)
Stockholders' equity note, subscriptions receivable  (8,822)    
Other undisclosed equity, attributable to parent   1,6218395,0005,000
Total equity:(3,779,059)(3,563,599)(3,117,179)(3,023,649)(3,067,573)(3,641,425)
TOTAL LIABILITIES AND EQUITY:72,365241,90760,32881,65113,10198,518

Income Statement (P&L) (USD)

9/30/2024
TTM
6/30/2024
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Operating expenses(1,536,049)(1,451,094)(1,776,645)(1,990,870)(1,812,143)(3,494,260)
Operating loss:(1,536,049)(1,451,094)(1,776,645)(1,990,870)(1,812,143)(3,494,260)
Nonoperating expense(413,611)(1,171,149)(1,013,762)(722,194)(327,219)(1,381,191)
Other nonoperating expense      (1,381,191)
Interest and debt expense54,56517,15825,969(17,503)50,60767,123
Loss from continuing operations before equity method investments, income taxes:(1,895,095)(2,605,085)(2,764,438)(2,730,567)(2,088,755)(4,808,328)
Other undisclosed income (loss) from continuing operations before income taxes(54,565)(17,158)(25,969)17,503(50,607) 
Loss from continuing operations before income taxes:(1,949,660)(2,622,243)(2,790,407)(2,713,064)(2,139,362)(4,808,328)
Income tax benefit129,132129,140129,84154,977113,415134,728
Loss from continuing operations:(1,820,528)(2,493,103)(2,660,566)(2,658,087)(2,025,947)(4,673,600)
Loss before gain (loss) on sale of properties:(2,658,087)(2,025,947)(4,673,600)
Net loss:(1,820,528)(2,493,103)(2,660,566)(2,658,087)(2,025,947)(4,673,600)
Other undisclosed net loss attributable to parent     (391,749)(67,123)
Net loss attributable to parent:(1,820,528)(2,493,103)(2,660,566)(2,658,087)(2,417,696)(4,740,723)
Preferred stock dividends and other adjustments(192,960)(234,876)(466,273)(700,340)  
Net loss available to common stockholders, diluted:(2,013,488)(2,727,979)(3,126,839)(3,358,427)(2,417,696)(4,740,723)

Comprehensive Income (USD)

9/30/2024
TTM
6/30/2024
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Net loss:(1,820,528)(2,493,103)(2,660,566)(2,658,087)(2,025,947)(4,673,600)
Other comprehensive income (loss)(25,295)74,80360,327149,345182,467 
Comprehensive loss:(1,845,823)(2,418,300)(2,600,239)(2,508,742)(1,843,480)(4,673,600)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(192,960)(328,742)(466,273)(700,340)(756,683)133,550
Comprehensive loss, net of tax, attributable to parent:(2,038,783)(2,747,042)(3,066,512)(3,209,082)(2,600,163)(4,540,050)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: